Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial
Andreas Burchert(Philipps University of Marburg), Christin Schütz(Philipps University of Marburg), Jolanta Dengler(Heidelberg University), Tim H. Brümmendorf(Heidelberg University), Sabrina Inselmann(Philipps University of Marburg), Andreas Hochhaus(Jena University Hospital), Stefan Hanzel(Kempten University of Applied Sciences), Cornelia Brendel(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Ekkehard Eigendorff(Jena University Hospital), Thomas Illmer(Center for Systems Biology Dresden), Regina Herbst(Klinikum Chemnitz), Thoralf Lange, Cornelius F. Waller(University Medical Center Freiburg), Gernot Freunek, Martin C. Müller(Universität Hamburg), Christian Dietz(Technische Universität Darmstadt), Ying Wang(Aerospace Center Hospital), Joëlle Guilhot(Inserm), Maria Elisabeth Goebeler(Universitätsklinikum Würzburg), Susanne Saußele(University of Mannheim), François Xavier Mahon(Centre Hospitalier Universitaire de Bordeaux), Florian Finkernagel(Philipps University of Marburg)
Cited by 9
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573